Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 2
2015 2
2016 2
2017 4
2018 3
2019 9
2020 5
2021 8
2022 6
2023 4
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Distler O, et al. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112379 Free article. Clinical Trial.
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Dorman SE, et al. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. N Engl J Med. 2021. PMID: 33951360 Free PMC article. Clinical Trial.
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.
Chang VK, Imperial MZ, Phillips PPJ, Velásquez GE, Nahid P, Vernon A, Kurbatova EV, Swindells S, Chaisson RE, Dorman SE, Johnson JL, Weiner M, Sizemore EE, Whitworth W, Carr W, Bryant KE, Burton D, Dooley KE, Engle M, Nsubuga P, Diacon AH, Nhung NV, Dawson R, Savic RM; AIDS Clinical Trial Group; Tuberculosis Trials Consortium. Chang VK, et al. Nat Commun. 2024 Oct 30;15(1):9400. doi: 10.1038/s41467-024-53273-7. Nat Commun. 2024. PMID: 39477924 Free PMC article. Clinical Trial.
Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes.
Paradkar MS, Pradhan NN, Balaji S, Gaikwad SN, Chavan A, Dharmashale SN, Sahasrabudhe T, Lokhande R, Deshmukh SA, Barthwal M, Atre S, Raskar SS, Sawant TU, Gupte AN, Kakrani A, Golub J, Padmapriyadarsini C, Gupta A, Gupte NA, Mave V. Paradkar MS, et al. Among authors: lokhande r. Ann Am Thorac Soc. 2023 Dec;20(12):1760-1768. doi: 10.1513/AnnalsATS.202302-144OC. Ann Am Thorac Soc. 2023. PMID: 38038600
Importance of Therapeutic Drug Monitoring of Rifampicin.
Chawla PK, Udwadia ZF, Soman R, Mahashur AA, Amale RA, Dherai AJ, Lokhande RV, Naik PR, Ashavaid TF. Chawla PK, et al. Among authors: lokhande rv. J Assoc Physicians India. 2016 Aug;64(8):68-72. J Assoc Physicians India. 2016. PMID: 27762112 Review.
Cascade of care for people with TB and diabetes in India.
Atre S, Barthwal M, Gaikwad S, Sawant T, Sahasrabudhe T, Kakrani A, Lokhande R, Deshmukh S, Raskar S, Hodgar B, Jadhav V, Gupte N, Gupta A, Golub J, Mave V. Atre S, et al. Among authors: lokhande r. Int J Tuberc Lung Dis. 2022 Aug 1;26(8):787-788. doi: 10.5588/ijtld.22.0180. Int J Tuberc Lung Dis. 2022. PMID: 35898132 No abstract available.
Coupled cluster-inspired geminal wavefunctions.
Gaikwad PB, Kim TD, Richer M, Lokhande RA, Sánchez-Díaz G, Limacher PA, Ayers PW, Miranda-Quintana RA. Gaikwad PB, et al. Among authors: lokhande ra. J Chem Phys. 2024 Apr 14;160(14):144108. doi: 10.1063/5.0202035. J Chem Phys. 2024. PMID: 38597308
Characterising cause of death among people treated for drug-susceptible TB in India.
Cox SR, Padmapriyadarsini C, Mave V, Seth B, Thiruvengadam K, Gaikwad S, Sahasrabudhe TR, Sane M, Tornheim JA, Shrinivasa BM, Lokhande R, Barthwal MS, Shivakumar SVBY, Krishnan S, Santhappan R, Kinikar A, Kakrani AL, Paradkar M, Bollinger RC, Sekar K, Gupte AN, Hanna LE, Gupta A, Golub JE. Cox SR, et al. Among authors: lokhande r. Int J Tuberc Lung Dis. 2023 Jan 1;27(1):78-80. doi: 10.5588/ijtld.22.0454. Int J Tuberc Lung Dis. 2023. PMID: 36853129 No abstract available.
46 results